| Success story

Finnish biotech expands to the Basel Area







Country of origin


UPM Biomedicals specializes in renewable alternatives to fossil materials and operates in numerous sectors. Recently, they opened a lab in Allschwil in the canton of Basel-Landschaft at the Switzerland Innovation Park Basel Area Main Campus.

The Finnish company UPM Biomedicals decided to expand to the Switzerland Innovation Park Basel Area Main Campus to establish the Basel Area as its base for operations in continental Europe. The Basel Area serves as a ‘new bridgehead’ for UPM Biomedicals.

The Director of UPM Biomedicals Johana Kuncová-Kallio also shared the following reason for settling:

Arriving in the Basel Area, one of the most dynamic life sciences clusters in the world, means that we are close to our customers in continental Europe. We gain access to the local talent pool and become part of the life sciences community here. With a location in the heart of European pharma, we can easily collaborate on novel solutions for healthcare.

Johannna Kuncová-KallioDirector of UPM Biomedicals

More about UPM Biomedicals

Founded in 1996 in Finland, UPM Biomedicals is the forerunner in producing high-quality nanofibrillar cellulose for medical and life science applications.  Their products store carbon throughout their lifecycle, particularly when recycled multiple times. With a focus on sustainability, UPM Biomedicals has demonstrated a commitment to recycling or recovering 90% of all process waste and achieving an 11% reduction in CO2 emissions in 2021. The company actively collaborate with universities, research centres and industrial partners on future innovations and products in drug screening, personalized medicine, advanced cell therapies, 3D bioprinting, tissue engineering and advanced wound care.

UPM Biomedicals is part of UPM, the Biofore Company, a global leader in renewable and recyclable materials. The holding employs approximately 17,200 employees worldwide and operates in more than 11 countries.

Do you have a question? We'd like to hear from you.